1.
Davies SJ, Bryan J, Phillips L, Russell GI: Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996;11:498–506.
2.
Selgas R, Fernandez-Reyes MJ, Bosque E, Bajo MA, Borrego F, Jimenez C, Del Peso G, De Alvaro F: Functional longevity of the human peritoneum: How long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study. Am J Kidney Dis 1994;23:64–73.
3.
Rubin J, Herrera GA, Collins D: An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1991;18:97–102.
4.
Verger C, Brunschvicg O, Le Charpentier Y, Lavergne A, Vantelon J: Structural and ultrastructural peritoneal membrane changes and permeability alterations during continuous ambulatory peritoneal dialysis. Proc Eur Dial Transplant Assoc 1981;18:199–205.
5.
Mateijsen MA, van der Wal AC, Hendriks PM, Zweers MM, Mulder J, Struijk DG, Krediet RT: Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999;19:517–525.
6.
Combet S, Miyata T, Moulin P, Pouthier D, Goffin E, Devuyst O: Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. J Am Soc Nephrol 2000;11:717–728.
7.
Honda K, Nitta K, Horita S, Yumura W, Nihei H: Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 1996;72:171–176.
8.
Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT: Peritoneal Biopsy Study Group: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002;13:470–479.
9.
De Vriese AS, Mortier S, Lameire NH: Neoangiogenesis in the peritoneal membrane: Does it play a role in ultrafiltration failure? Nephrol Dial Transplant 2001;16:2143–2145.
10.
Margetts PJ, Gyorffy S, Klob M, Yu L, Hoff CM, Holmes CJ, Gauldie J: Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol 2002;13:721–728.
11.
De Vriese AS, Tilton RG, Stephan CC, Lamaire N: Diabetes-induced microvascular proliferation and hyperpermeability in the peritoneum: Role of vascular endothelial growth factor. J Am Soc Nephrol 2001;12:1734–1741.
12.
Krediet RT, Zweers MM, van der Wal AC, Struijk DG: Neoangiogenesis in the peritoneal membrane. Perit Dial Int 2000;20(suppl 2):S19–25.
13.
Davies SJ, Phillips L, Naish PF, Russell GI: Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001;12:1046–1051.
14.
Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor and its receptors. FASEB J 1999;13:9–22.
15.
De Vriese AS, Mortier S, Lameire NH: Glucotoxicity of the peritoneal membrane: The case for VEGF. Nephrol Dial Transplant 2001;16:2299–2302.
16.
Selgas R, del Peso G, Bajo MA, Castro MA, Molina S, Cirugeda A, Sanchez-Tomero JA, Castro MJ, Alvarez V, Corbi A, Vara F: Spontaneous VEGF production by cultured peritoneal mesothelial cells from patients on peritoneal dialysis. Perit Dial Int 2000;20:798–801.
17.
Zweers MM, de Waart DR, Smit W, Struijk DG, Krediet RT: Growth factors VEGF and TGF-beta1 in peritoneal dialysis. J Lab Clin Med 1999;134:124–132.
18.
Zweers MM, Struijk DG, Smit W, Krediet RT: Vascular endothelial growth factor in peritoneal dialysis: A longitudinal follow-up. J Lab Clin Med 2001;137:125–132.
19.
Inagi R, Miyata T, Yamamoto T, Suzuki D, Urakami K, Saito A, van Ypersele de Strihou C, Kurokawa K: Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: Role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 1999;463:260–264.
20.
Mortier S, De Vriese AS, Schaub TS, Van de Voorde J, Passlick-Deetjen J, Lameire NH: Hemodynamic effects of conventional and new peritoneal dialysis solutions on the microcirculation of the rat peritoneal membrane: Role of acidity, buffer choice, glucose concentration and glucose degradation products. J Am Soc Nephrol 2002;13:480–489.
21.
Dawnay AB, Millar DJ: Glycation and advanced glycation end-product formation with icodextrin and dextrose. Perit Dial Int 1997;17:52–58.
22.
Friedlander MA, Wu YC, Schulak JA, Monnier VM, Hricik DA: Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end-stage renal disease. Am J Kidney Dis 1995;25:441–451.
23.
Linden T, Forsback G, Deppisch R, Henle T, Wieslander A: 3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis. Perit Dial Int 1998;18:290–293.
24.
Schalkwijk CG, Posthuma N, ten Brink HJ, ter Wee PM, Teerlink T: Induction of 1,2-dicarbonyl compounds, intermediates in the formation of advanced glycation end-products, during heat-sterilization of glucose-based peritoneal dialysis fluids. Perit Dial Int 1999;19:325–333.
25.
Lamb EJ, Cattell WR, Dawnay AB: In vitro formation of advanced glycation end products in peritoneal dialysis fluid. Kidney Int 1995;47:1768–1774.
26.
Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, Hayakawa H, Osaka N, Yamamoto H, Ogawa A, Kubo H, Shigematsu T, Sakai O, Horiuchi S: Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997;51:182–186.
27.
Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, Ikeda K, Horiuchi S: Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999;14:1541–1549.
28.
Park MS, Lee HA, Chu WS, Yang DH, Hwang SD: Peritoneal accumulation of AGE and peritoneal membrane permeability. Perit Dial Int 2000;20:452–460.
29.
Mandl-Weber S, Cohen CD, Haslinger B, Kretzler M, Sitter T: Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells. Kidney Int 2002;61:570–578.
30.
Barre DE, Chen C, Cooker L, Moberly JB: Decreased in vitro formation of AGEs with extraneal solution compared to dextrose-containing peritoneal dialysis solutions. Adv Perit Dial 1999;15:12–16.
31.
Lee JH, Reddy DK, Saran R, Moore HL, Twardowski ZJ, Nolph KD, Khanna R: Advanced glycosylation end-products in diabetic rats on peritoneal dialysis using various solutions. Perit Dial Int 2000;20:643–651.
32.
Posthuma N, Verbrugh HA, Donker AJ, van Dorp W, Dekker HA, Peers EM, Oe PL, ter Wee PM: Peritoneal kinetics and mesothelial markers in CCPD using icodextrin for daytime dwell for two years. Perit Dial Int 2000;20:174–180.
33.
Millar DJ, Holmes C, Faict D, Dawnay A: Comparison of in vitro AGE formation between standard PD fluid and a novel bicarbonate/lactate formulation. Adv Perit Dial 1998;14:191–194.
34.
Park MS, Kim JK, Holmes C, Weiss MF: Effects of bicarbonate/lactate solution on peritoneal advanced glycosylation end-product accumulation. Perit Dial Int 2000;20(suppl 5):S33–S38.
35.
Jonasson P, Braide M: A commercially available PD fluid with high pH and low GDP induces different morphological changes of rat peritoneum in intermittent PD. Adv Perit Dial 1998;14:48–53.
36.
Hekking LH, Zareie M, Driesprong BA, Faict D, Welten AG, de Greeuw I, Schadee-Eestermans IL, Havenith CE, van den Born J, ter Wee PM, Beelen RH: Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/lactate buffered solution. J Am Soc Nephrol 2001;12:2775–2786.
37.
Margetts PJ, Kolb M, Galt T, Hoff CM, Shockley TR, Gauldie J: Gene transfer of transforming growth factor-beta1 to the rat peritoneum: Effects on membrane function. J Am Soc Nephrol 2001;12:2029–2039.
38.
Pertovaara L, Kaipanen A, Mustonen T, Orpana A, Ferrara N, Saksela O, Alitalo K: Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 1994;269:6271–6274.
39.
Murohara T, Asahara T, Silver M, et al: Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998;101:2567–2578.
40.
Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC: Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997;100:3131–3139.
41.
Ziche M, Morbidelli L, Choudhuri R, et al: Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997;99:2625–2634.
42.
Greten J, Kreis I, Weisel K, Stier E, Schmidt AM, Stern DM, Ritz E, Waldherr R, Nawroth PP: Receptors for advance glycation end-products (AGE)-expression by endothelial cells in non-diabetic uraemic patients. Nephrol Dial Transplant 1996;11:786–790.
43.
Abel M, Ritthaler U, Zhang Y, Deng Y, Schmidt AM, Greten J, Sernau T, Wahl P, Andrassy K, Ritz E: Expression of receptors for advanced glycosylated end-products in renal disease. Nephrol Dial Transplant 1995;10:1662–1667.
44.
Boulanger E, Wautier MP, Wautier JL, Boval B, Panis Y, Wernert N, Danze PM, Dequiedt P: AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 2002;61:148–156.
45.
Coles GA, O’Donoghue DJ, Pritchard N, Ogg CS, Jani FM, Gokal R, Cancarini GC, Maiorca R, Tranaeus A, De Vos C, Hopwood A, Faict D: A controlled trial of two bicarbonate-containing dialysis fluids for CAPD: Final report. Nephrol Dial Transplant 1998;13:3165–3171.
46.
Feriani M, Kirchgessner J, La Greca G, Passlick-Deetjen J, Bicarbonate CAPD Cooperative Group: Randomized long-term evaluation of bicarbonate-buffered CAPD solution: Kidney Int 1998;54:1731–1738.
47.
Lamb E, Cattell WR, Dawnay A: Glycated albumin in serum and dialysate of patients on continuous ambulatory peritoneal dialysis. Clin Sci (Colch) 1993;84:619–626.
48.
Kjellstrand P, Martinson E, Wieslander A, Holmquist B: Development of toxic degradation products during heat sterilization of glucose-containing fluids for peritoneal dialysis: influence of time and temperature. Perit Dial Int 1995;15:26–32.
49.
Gotloib L, Bar-Sella P, Shostak A: Reduplicated basal lamina of small venules and mesothelium of human parietal peritoneum: Ultrastructural changes of reduplicated peritoneal basement membrane. Perit Dial Bull 1985;5:212–215.
50.
Dobbie JW, Lloyd JK, Gall CA: Categorization of ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients. Adv Perit Dial 1990;6:3–12.
51.
Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR, Oreopoulos DG, Page D: Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. J Am Soc Nephrol 1998;9:1285–1292.
52.
Krediet RT: The peritoneal membrane in chronic peritoneal dialysis. Kidney Int 1999;55:341–356.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.